Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $13.37 Million

Brokerages expect that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will announce sales of $13.37 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Lexicon Pharmaceuticals’ earnings, with the highest sales estimate coming in at $16.58 million and the lowest estimate coming in at $10.17 million. Lexicon Pharmaceuticals reported sales of $25.21 million during the same quarter last year, which would suggest a negative year over year growth rate of 47%. The company is scheduled to issue its next earnings report on Thursday, May 2nd.

On average, analysts expect that Lexicon Pharmaceuticals will report full-year sales of $93.68 million for the current year, with estimates ranging from $58.47 million to $176.21 million. For the next year, analysts anticipate that the company will report sales of $103.38 million, with estimates ranging from $40.23 million to $152.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 911.43% and a negative net margin of 192.53%. The company had revenue of $17.10 million for the quarter, compared to analyst estimates of $13.33 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The firm’s revenue for the quarter was down 49.7% compared to the same quarter last year.

A number of equities research analysts have commented on LXRX shares. Citigroup restated a “buy” rating and issued a $14.00 target price on shares of Lexicon Pharmaceuticals in a research report on Tuesday, January 22nd. They noted that the move was a valuation call. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research report on Thursday, January 24th. Stifel Nicolaus reduced their target price on Lexicon Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, March 25th. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 25th. Finally, BidaskClub upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 17th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $17.13.

NASDAQ:LXRX traded down $0.08 on Monday, reaching $5.58. The company’s stock had a trading volume of 645,697 shares, compared to its average volume of 906,339. Lexicon Pharmaceuticals has a 12-month low of $4.25 and a 12-month high of $13.97. The company has a market capitalization of $593.00 million, a P/E ratio of -4.89 and a beta of 0.71.

Hedge funds have recently bought and sold shares of the stock. Pegasus Asset Management Inc. purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $66,000. Paloma Partners Management Co purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $73,000. CWM Advisors LLC raised its holdings in shares of Lexicon Pharmaceuticals by 30.2% in the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 3,030 shares during the period. D.A. Davidson & CO. purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $87,000. Finally, Metropolitan Life Insurance Co. NY raised its holdings in shares of Lexicon Pharmaceuticals by 409.3% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 11,862 shares during the period. Hedge funds and other institutional investors own 99.16% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Further Reading: Why is a lock-up period needed for an IPO?

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.